

| | | | | |
|--|--|--|--|--|
| Day 1 | | | | |
| 07.00 Registration | | | | |
| Level 8 | | | | |
| 08.30 - 09.00 Opening Ceremony Room: Montreal Ballroom, Level 11 Chairs: Julia Bruneau, Marina Klein, and Jason Grebely | | | | |
| 08.30 - 08.45 Welcome to the Conference | | | | |
| 08.45 - 08.50 Community Opening | | | | |
| 08.50 - 09.00 Awards | | | | |
| 09.00 - 10.45 Session A: Public Health and Epidemiology Room: Montreal Ballroom, Level 11 Chairs: Margaret Hellard, Burnet Institute, Australia and Matthew Hickman, University of Bristol, United Kingdom | | | | |
| 09.00 - 09.20 The changing landscape of drug use globally: Implications for hepatitis C elimination Louisa Degenhardt, UNSW Sydney, Australia | | | | |
| 09.20 - 09.25 Questions & Discussion | | | | |
| 09.25 - 09.45 Global progress towards hepatitis C elimination: success and challenges Margaret Hellard, Burnet Institute, Australia | | | | |
| 09.45 - 10.00 The Scottish Experience: Reduction in the Population Prevalence of Chronic HCV among People Who Inject Drugs Associated with Major Scale-Up of Direct-Acting Antiviral Therapy in Community Drug Services: Real World Data Norah Palmateer, Glasgow Caledonian University, Glasgow | | | | |
| 10.00 - 10.10 The Georgian experience. Not just cure. The broader benefits of providing hepatitis C treatment in needle and syringe programs services Maia Butsashvili, Health Research Union, Georgia | | | | |
| 10.10 - 10.20 The Iceland experience. Getting the band together: The importance of bringing together government, hepatology, infectious diseases, drug and alcohol services and the prison sector to engage with people who inject drugs in hepatitis C care Sigurdur Olafsson, Landspítali University Hospital, Iceland | | | | |
| 10.20 - 10.30 Questions & Discussion | | | | |
| 10.30 - 10.45 Life and loss in the race to elimination: What does viral elimination potentiate and what does it leave behind? Kari Lancaster, Centre For Social Research in Health, UNSW, Australia | | | | |
| 10.45 - 11.15 Coffee Break and Poster Viewing | | | | |
| Level 8 | | | | |
| 11.15 - 12.15 Session B: Mathematical Modelling to Inform Practice and Policy Room: Montreal Ballroom, Level 11 Chairs: Tim Rhodes and Kari Lancaster | | | | |
| 11.15 - 11.35 How can mathematical modelling be used to better inform research, practice and policy in hepatitis C and drug user health? Peter Vickerman, University of Bristol, United Kingdom | | | | |
| 11.35 - 12.15 Panel - Modelling Elimination: What Can Models Do? What Effects Do They Make? Moderator: Tim Rhodes, London School of Hygiene and Tropical Medicine, United Kingdom Panellists: Natasha Martin, University of California San Diego; Nick Scott, Burnet Institute, Australia; Homie Razavi, Centre for Disease Analysis, United States; Kari Lancaster, University of New South Wales, Australia; John Dillon, University of Dundee, United Kingdom; Tracy Swan, Consultant, United States; Niklas Luhmann, World Health Organisation, Switzerland | | | | |
| 12.15 - 14.00 Lunch & Poster Viewing | | | | |
| Level 8 | | | | |
| 12.45 - 13.45 Industry Sponsored Symposium: Working together towards HCV elimination in substance users: a multidisciplinary approach | | | | |
| Room: Fortifications, Level 9 | | | | |
| 14.00 - 15.20 Session C: Progress towards hepatitis C elimination Room: Montreal A & B, Level 11 Chairs: Philip Bruggeman and Adalina Arsenia | | | | |
| 14.00 - 14.15 How the elimination of a virus came to be: Modelling and the life of targets Tim Rhodes, UNSW, Australia | | | | |
| 14.15 - 14.30 Recent opioid agonist therapy and hepatitis C virus treatment uptake among people who inject drugs with chronic hepatitis C infection in a population based data linkage study Sofia Bartlett, BC Centre For Disease Control, Canada | | | | |
| 14.30 - 14.45 An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study Marvam Alavi, The Kirby Institute, UNSW Sydney, Australia | | | | |
| 14.45 - 14.50 The evolving hepatitis C care cascade in a real-world setting: results for the period 2003-2017 from Free Clinic Antwerp Catharina Mathel, Free Clinic Antwerp, Belgium | | | | |
| 14.50 - 14.55 High uptake of direct-acting antiviral therapy for hepatitis C virus and reduction in population-level viremic prevalence: Progress toward achieving hepatitis C elimination among people who inject drugs in Australia Heather Valerio, The Kirby Institute, UNSW Sydney, Australia | | | | |
| 14.55 - 15.00 Early impact of direct-acting antivirals on chronic hepatitis C prevalence among people who inject drugs in England: Real world data, 2011-2017 Megan Bardsley, Public Health England, United Kingdom | | | | |
| 15.00 - 15.05 Opportunities for engaging patients in care along the hepatitis C cascade of care Alisa Pedrana, Burnet Institute, Australia | | | | |
| 15.05 - 15.10 A one-stop community-based approach for HCV screening, diagnosis and treatment among people who inject drugs in Iran: The Rostam study Samira Hosseini Hooshvar, The Kirby Institute, UNSW Sydney, Australia | | | | |
| 15.10 - 15.15 Decreasing hepatitis C incidence and prevalence through enhancing HCV care and treatment among HIV co-infected individuals: The CO-EC study outcomes Joseph Doyle, Burnet Institute, Australia | | | | |
| 15.15 - 15.20 Engaging drug using communities to scale up diagnosis and inform national HIV/HCV elimination efforts Annette Gaudino, Treatment Action Group, United States | | | | |
| 14.00 - 15.20 Session D: Ways to improve HCV testing, treatment and care Room: Montreal C & D, Level 11 Chairs: Mal Krutson and Lisa Leffort | | | | |
| 14.00 - 14.15 Task shifting in HCV testing and research: improving knowledge of HCV status through a peer outreach hepatitis C point of care project in Toronto, Canada Jennifer Broad, South Riverdale Community Health Centre, Canada | | | | |
| 14.15 - 14.30 Maximising adherence to direct-acting antivirals among street-based and marginalised clients: The results of daily dosing Phillip Read, Kirkeaton Road Centre, Australia | | | | |
| 14.30 - 14.45 Changes in attitudes, knowledge and everyday life throughout direct-acting antiviral treatment for hepatitis C: a longitudinal qualitative study Stelliana Goutzamanis, Burnet Institute, Australia | | | | |
| 14.45 - 14.50 Factors that influence people who use drugs' experiences with direct-acting antiviral treatment for hepatitis C: a qualitative study in Vancouver, Canada Rod Knight, National Prisons Hepatitis Network, Australia | | | | |
| 14.50 - 14.55 Dispensing mode and hepatitis C direct acting antiviral treatment completion John Koo, Vancouver Coastal Health, Canada | | | | |
| 14.55 - 15.00 HCV support groups: do they still have a role in the DAA era? Tianna Magel, Vancouver Infectious Diseases Centre, Canada | | | | |
| 15.00 - 15.05 Peerswellness: indigenous model for supportive HCV and HIV care Sadeem Fayed, Simon Fraser University, Canada | | | | |
| 15.05 - 15.10 A two-eyed seeing approach to wholistic healing and wellness for people with drug use experience Matthew Fischer, Indigenous Wellness Research Group, Canada | | | | |
| 15.10 - 15.15 Enhanced self-efficacy for HCV management among people participating an HCV education program focused on drug and alcohol and primary care settings Nikitah Habraken, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Australia | | | | |
| 15.15 - 15.20 Accessible care intervention for engaging people who inject illicit drugs in hepatitis C virus care: preliminary results from a randomized clinical trial Benjamin Eckhardt, New York University School Of Medicine, United States | | | | |
| 14.00 - 15.20 Session E: Models of care to enhance engagement in care Room: Room: Fortifications, Level 9 Chairs: Marie-ève Goyar and Martin Käberg | | | | |
| 14.00 - 14.15 The Kombi Clinic – It's the end of the road for Hepatitis C Mary O'Flynn, Kombi Clinic, Australia | | | | |
| 14.15 - 14.30 Effective DAA HCV Treatment and Care Model Among People Who Inject Drugs in Most Hard-to-Reach Conflict Areas in Northern Myanmar Su Su Aung, Asian Harm Reduction Network, Myanmar | | | | |
| 14.30 - 14.45 Addressing the HCV cascade of care in vulnerable populations with poor access to healthcare in Madrid through of a point of care in a one step Jorne Valencia, Harm reduction Unit "SMASD", Subdirección General de Adicciones, Spain | | | | |
| 14.45 - 14.50 National Prisons Hepatitis Network - Facilitating enhanced infrastructure and scale-up of HCV treatment in Australian prisons: towards national elimination Yumi Sheehan, National Prisons Hepatitis Network, Australia | | | | |
| 14.50 - 14.55 Police are responsive to hepatitis C prevention: Police sensitization with a hepatitis C entry have proven to be more effective in Nairobi, Kenya Wangari Kimemia, Medecins Du Monde, Kenya | | | | |
| 14.55 - 15.00 Establishing an Integrated Care Clinic for HCV-infected People Who Actively Inject Drugs (PWID) at a Harm Reduction Center in Washington, DC (ANCHOR Model) Rachel Silk, University Of Maryland, United States | | | | |
| 15.00 - 15.05 Hepatitis C treatment integration with harm reduction services in Georgia: Preliminary findings Maia Butsashvili, Health Research Union, Georgia | | | | |
| 15.05 - 15.10 Good practices in health response to HCV in a harm reduction program Hugo Faria, Ares Do Pinhal, Portugal | | | | |
| 15.10 - 15.15 Partnering with consumers: The development of a primary health care hepatitis C treatment model within a peer-based needle and syringe program John Lockwood, Kirkeaton Road Centre, Australia | | | | |
| 15.15 - 15.20 A community-based approach to viral hepatitis in central Appalachia Jane Crowe, Knox Country Health Department, United States | | | | |
| 15.20 - 16.15 Coffee Break & Poster Tour | | | | |
| Level 8 | | | | |
| 15.30 - 16.00 Poster Tour 1: | | | | |
| 15.30 - 15.35 | | | | |
| 15.35 - 15.40 | | | | |
| 15.40 - 15.45 | | | | |
| 15.45 - 15.50 | | | | |
| 15.50 - 15.55 | | | | |
| 15.55 - 16.00 | | | | |
| 15.30 - 16.00 Poster Tour 2: | | | | |
| 15.30 - 15.35 | | | | |
| 15.35 - 15.40 | | | | |
| 15.40 - 15.45 | | | | |
| 15.45 - 15.50 | | | | |
| 15.50 - 15.55 | | | | |
| 15.55 - 16.00 | | | | |
| 16.15 - 17.45 Session F: Prevention of Hepatitis C Room: Montreal A & B, Level 11 Chairs: Natasha Martin and Niklas Luhmann | | | | |
| 16.15 - 16.35 Hepatitis C reinfection among people who inject drugs: Should we worry? Havard Midgard, Oslo University Hospital, Norway | | | | |
| 16.15 - 16.20 Territorial Acknowledgement /Welcome to Territory | | | | |
| 16.20 - 16.25 Opening Blessing Elder Sharon Jinkerson Brass, Key First Nation, Canada & Sadeem Fayed, Indigenous Wellness Research Group, Canada | | | | |
| 16.25 - 16.35 Overview Alexandra King, University of Saskatchewan, Canada & Renée Masching, Canadian Aboriginal AIDS Network, Canada | | | | |
| 16.35 - 16.55 Developing new pathways of care in addiction services: a partnership between Onetokon Healing Lodge and the Centre hospitalier de l'Université de Montréal Arlette Ven Den Hende, Onetokon Healing Lodge, Canada & Stéphanie Marsan, Centre hospitalier de l'Université de Montréal, Canada | | | | |
| 16.35 - 16.55 The critical role of peers in facilitating care for people who use drugs Jennifer Broad, South Riverdale Community Health Centre, Canada | | | | |
| 16.55 - 17.15 What does the future hold for a hepatitis C vaccine? Naglaa Shouky, Université de Montréal, Canada | | | | |
| 16.55 - 17.15 Dried blood spots and disruptive innovation: Empowerment of Indigenous communities to address the colonial etiology of hepatitis C Anne Beck, Kitchenuhmaykoosib Inninuwug (Big Trout) First Nation, Canada & John Kim, National Laboratory for HIV Reference Services, Public Health Agency of Canada, Canada | | | | |
| 16.55 - 17.15 How can knowledge translation be used to enhance the uptake of interventions in marginalized populations? Catherine Hankins, McGill University, Canada | | | | |
| 17.15 - 17.45 Questions & Discussion | | | | |
| 17.15 - 17.35 Healing through research: Indigenous research methodologies in the substance use and hepatitis C space Elder Sharon Jinkerson Brass, Key First Nation, Canada & Sadeem Fayed, Indigenous Wellness Research Group, Canada | | | | |
| 17.35 - 17.45 Questions & Discussion | | | | |
| 17.45 - 19.00 Welcome Reception & Poster Viewing | | | | |

| | | | | | | | |
|----------------------|--|----------------------|---|---|---|----------------------|--|
| Day 2 | HCV Diagnosis, Linkage to Care and Treatment | | | | | | |
| 07.30 | Registration | | | | | | |
| 08.00 - 08.45 | Industry Sponsored Symposium | | | | | | |
| | Room: Fortifications, Level 9 | | | | | | |
| 09.00 - 10.45 | Session I: Moving from clinical trials to the real-world | | | | | | |
| | Room: Montreal Ballroom, Level 11 | | | | | | |
| | Chairs: Shruti Mehta and Gregory Dore | | | | | | |
| 09:00 - 09:20 | Overcoming barriers to integrating hepatitis C testing, linkage to care and treatment into existing services: success stories from low and middle income countries Sunil Solomon, Johns Hopkins University, United States | | | | | | |
| 09:20 - 09:40 | Moving from clinical trials to the real world: Effectiveness research for hepatitis c Lisa R. Metsch, Columbia University, United States | | | | | | |
| 09:40 - 10:00 | Skype Presentation: Supporting enhanced efforts to address hepatitis C and health for people who use drugs through strong government leadership Ricardo Baptiste Leite, UNITE, Portugal | | | | | | |
| 10:00 - 10:15 | Questions & Discussion | | | | | | |
| 10:15 - 10:30 | Australia will need to increase testing to achieve hepatitis C elimination Nick Scott, Burnet Institute, Australia | | | | | | |
| 10:30 - 10:45 | Barriers and facilitators to engaging in HCV management and DAA therapy among general practitioners and drug and alcohol specialists - The practitioner experience Alison Marshall, The Kirby Institute, UNSW Sydney, Australia | | | | | | |
| 10.45 - 11.15 | Coffee Break & Poster Viewing | | | | | | |
| | Level 8 | | | | | | |
| 11.15 - 12.15 | Session K: Hepatitis C risk and prevention | 11.15 - 12.15 | Session L: Enhancing hepatitis C testing and linkage to care | 11.15 - 12.15 | Session J Workshop 1: Peers facilitating access to their criminalized communities improving the hep c cascade of care: How to meaningfully engage and involve people with lived experience (PWLE) in your programs | 11.15 - 12.15 | Session J Workshop 2: From the Frontline: A networking session |
| | Room: Montreal A & B, Level 11 | | Room: Montreal C & D, Level 11 | | Room: Fortifications, Level 9 | | Room: Ville-Marie, Level 9 |
| | Chairs: Hannah Fraser and Behzad Hajarizadeh | | Chairs: Valerie Martel-Laferriere and Joshua Barocas | | Chairs: TBC | | Chairs: TBC |
| 11.15 - 11.30 | Association between short-term housing patterns and hepatitis c acquisition: findings from a cohort of people who inject drugs in Montréal, Canada Emmanuel Fortier, CHUM Research Centre, Canada | 11.15 - 11.30 | Making Oraquick quicker: A hepatitis C point-of-care test reduced to five minutes for viremic individuals Aaron Vanderhoff, Viral Hepatitis Care Network, Canada | This session will provide an opportunity to meet, network and collaborate with other service providers, program planners, community members and researchers who have a focus on front-line services and programs. You'll engage in facilitated discussions on approaches in four settings: prisons, harm reduction and needle-syringe programs, addiction medicine and opioid substitution therapy, and mobile and community-based. | This session is presented by INHSU and CATIE. CATIE is Canada's source for HIV and hepatitis C information | | |
| 11.30 - 11.45 | Diversity of detention patterns among people who inject drugs and the associated risk with incident hepatitis c virus (HCV) infection: Implications for HCV prevention Andreea Adelina Arteni, University Of Montréal, Canada | 11.30 - 11.45 | Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load fingerstick point-of-care assay: Facilitating a more rapid time to diagnosis Jason Grebely, The Kirby Institute, UNSW Sydney, Australia | | | | |
| 11.45 - 12.00 | Modelling the impact of prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania Hannah Fraser, University of Bristol, United Kingdom | 11.45 - 12.00 | Targeted testing pathways improve hepatitis C diagnosis rates Emma Robinson, University Of Dundee, United Kingdom | | | | |
| 12.00 - 12.05 | HIV and HCV among people who inject drugs in Ukraine: a stabilization or a calm before the storm? Marina Kornilova, Alliance For Public Health, Ukraine | 12.00 - 12.05 | Cost-effectiveness of hepatitis c virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya Jack Stone, University Of Bristol, United Kingdom | | | | |
| 12.05 - 12.10 | HCV among people who inject drugs in France: Acting on risk environment in an evolving crisis Marie Jauffret-Roustide, Inserm, France | 12.05 - 12.10 | The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK Zoe Ward, University Of Bristol, United Kingdom | | | | |
| 12.10 - 12.15 | The Brazilian syndemics of crack use, HIV and HCV Alexandra Almeida, SDSU, United States | 12.10 - 12.15 | Using a systems-thinking approach to elucidate programme theory underpinning the effectiveness of Superdot-C: a pharmacy-led test and treat pathway for PWIDS with Andrew Radley, NHS Tayside, United Kingdom | | | | |
| 12.15 - 14.00 | Lunch and Poster Viewing | | | | | | |
| | Level 8 | | | | | | |
| 12.45 - 13.45 | Industry Sponsored Symposium: Transforming HCV care: the power of collaboration | | | | | | |
| | Room: Fortifications, Level 9 | | | | | | |
| 14.00 - 15.00 | Session M: Hepatitis prevention, treatment, and care in prisons | 14.00 - 15.00 | Session N: Enhancing hepatitis C treatment | 14.00 - 15.00 | Session O: Models of care: targeted interventions in various settings | 14.00 - 15.00 | Session: Peer-based models of care: Learning from our communities |
| | Room: Montreal A & B, Level 11 | | Room: Montreal C & D, Level 11 | | Room: Fortifications, Level 9 | | Room: Ville-Marie, Level 9 |
| | Chairs: Andrew Lloyd and Lisa Barrett | | Chairs: Brian Conway and Anne Øvrehus | | Chairs: Alexandra King and Shashi Kapadia | | Chairs: Jude Byrne and Matthew Bonn |
| 14.00 - 14.15 | The hepatitis c virus (HCV) cascade of care in the New York City (NYC) jail system Justin Chan, Correctional Health Services, NYC Health + Hospitals, United States | 14.00 - 14.15 | Nurse-led, community-based hepatitis c treatment is feasible and effective among people who inject drugs and their injecting network: the HCV treatment and prevention (TAP) study Joseph Doyle, Burnet Institute, Australia | 14.00 - 14.15 | Approaches to providing hepatitis C viremia testing to people who inject drugs in Georgia, Head Start (Hepatitis Elimination Through Access to Diagnostics) Georgia Maia Japaridze, FIND, Switzerland | 14.00 - 14.15 | Peer-led approach on treatment of Hepatitis C Manasseh Muriithi, MDM-france, Kenya |
| 14.15 - 14.30 | Injecting culture following prison-wide hepatitis C treatment scale-up: negotiating risk after cure Lise Lafferty, UNSW Sydney, Australia | 14.15 - 14.30 | Comparing trial designs for HCV treatment as prevention: An empirical evaluation Natasha Martin, University Of California San Diego, United States | 14.15 - 14.30 | Increasing access to addiction services for Indigenous communities in Quebec: An integrated model of care between Onen'to:kon Healing Lodge, Stephanie Marsan, Centre hospitalier de l'Université De Montréal, Canada | 14.15 - 14.30 | Methadone maintenance treatment program (MMTP) in Nepal: Role of user-led organizations in engaging and empowering MMTP patients Ranjit Tiwari, National User Network of Nepal, Nepal |
| 14.30 - 14.45 | 'Set up to fail': the post-release experience of prisoners with a history of injection drug use Sophia Schroeder, Burnet Institute, Australia | 14.30 - 14.45 | Promise and pharmaceuticalisation in the era of direct-acting antivirals Jake Rance, Centre For Social Research In Health, Australia | 14.30 - 14.45 | Micro-elimination of Hepatitis C among people who use drugs in an Indigenous community in Saskatchewan Canada Noreen Reed, Ahtakakooop Health Clinic, Canada | 14.30 - 14.45 | A peer-based support-model for HCV treatment for PWID, integrated into a public healthcare facility in Hanoi, Vietnam Mathilde Laval, Medecins Du Monde, France |
| 14.45 - 14.50 | Perceived barriers to and facilitators of HCV treatment uptake in jail and linkage to HCV care after incarceration: a qualitative study Matthew Akiyama, Montefiore Medical Center, United States | 14.45 - 14.50 | Real-world outcomes in Patients with Chronic Hepatitis C Virus Infection with Opioid Substitution Therapy, Mental Disorders, or Alcohol use Disorder Treated with Glecaprevir/Pibrentasvir: Data From The German Hepatitis C-Registry Stefan Christensen, CIM Münster, Germany | 14.45 - 14.50 | Successful treatment of hepatitis c among people who inject drugs in Nairobi, Kenya Gladys Ngwei, Medecins Du Monde, Kenya | 14.45 - 14.50 | The Hepatitis Bus – A Norwegian drug user initiative Ronny Bjørnstad, proLAR Nett, Norway |
| 14.50 - 14.55 | Enhancing linkage to hepatitis C care upon release from Canadian provincial prisons: the population-level impact on hepatitis C transmission among people who inject drugs in Montréal Arnaud Godin, McGill University, Canada | 14.50 - 14.55 | Real-world outcomes from people who use drugs with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: A pooled analysis of post-marketing observational studies Juliette Foucher, Hopital de Haut Leveque, France | 14.50 - 14.55 | Pharmacist-led HCV screening, diagnosis and treatment in an opioid substitution therapy outpatient pharmacy Colter Young, Shoppers Drug Mart, Canada | 14.50 - 14.55 | Community-based organization spearheads efforts to translate HCV interventions to prison settings in Jakarta Caroline Thomas, Koalisi Satu Hati, Indonesia |
| 14.55 - 15.00 | Disparities in Hepatitis C virus (HCV) care across Quebec's provincial prisons: Implications for HCV micro-elimination Nadine Kronfli, McGill University, Canada | 14.55 - 15.00 | Actively injecting PWID who use stimulants can be successfully treated for HCV infection Sigurdur Olafsson, Landspítali University Hospital, Iceland | 14.55 - 15.00 | Evaluation of the Xpert HCV Viral Load Fingerstick assay in the harm reduction setting in Catalonia, Spain Verónica Saludes, Germans Trias I Pujol University Hospital Research Institute (igtp), Spain | 14.55 - 15.00 | Can patient groups lead diagnosis and treatment in prisons of resource limited settings? We are doing it! Nalinikanta Rajkumar, Community Network For Empowerment (CoNE), India |
| 15.00 - 15.45 | Coffee Break and Poster Tour | | | | | | |
| | Level 8 | | | | | | |
| 15.10 - 15.40 | Poster Tour 3: | | | 15.10 - 15.40 | Poster Tour 4: | | |
| 15.10 - 15.15 | | | | 15.10 - 15.15 | | | |
| 15.15 - 15.20 | | | | 15.15 - 15.20 | | | |
| 15.20 - 15.25 | | | | 15.20 - 15.25 | | | |
| 15.25 - 15.30 | | | | 15.25 - 15.30 | | | |
| 15.30 - 15.35 | | | | 15.30 - 15.35 | | | |
| 15.35 - 15.40 | | | | 15.35 - 15.40 | | | |
| 15.45 - 17.15 | Session P: Prisons | 15.45 - 17.15 | Session Q: Strategies to enhance testing and diagnosis | 15.45 - 17.15 | Session R: Neglected but not forgotten: innovative ways to engage women who use drugs into HCV care (supported by IAS) | | |
| | Room: Montreal A & B, Level 11 | | Room: Montreal C & D, Level 11 | | Room: Fortifications, Level 9 | | |
| | Chairs: Nadine Kronfli and Matthew Akiyama | | Chairs: Jason Grebely and Karine Lacombe | | Chairs: Marina Klein and Judy Chang | | |
| 15.45 - 16.05 | Tackling prisoner health via an upstream public health approach Prem Thuraiarajah, Changi General Hospital, Singapore | 15.45 - 16.05 | Diagnostics for hepatitis C: Where do we stand and what lies ahead? Sonjelle Shilton, The Foundation for Innovative New Diagnostics, Switzerland | 15.45 - 15.50 | Myanmar Video Médecins du Monde | | |
| 16.05 - 16.25 | Project ECHO as a model for hepatitis care in the prisons Karia Thornton, University of New Mexico, United States | 16.05 - 16.25 | Expanding hepatitis C testing and diagnosis for people who inject drugs in low- and middle-income countries: Successes and challenges Ernst Wisse, Medecins Du Monde, France | 16.10 - 16.30 | Gender-based approaches to harm reduction and anti-violence programs for women who use drugs in Ukraine Velta Parkhomenko, Club Eney, Ukraine | | |
| 16.25 - 16.45 | Hepatitis C testing and treatment in correctional centers in the United States Anne Spaulding, Emory University, United States | 16.25 - 16.45 | How can we facilitate the implementation of novel testing strategies and diagnosis beyond the laboratory? Philip Cunningham, St Vincent's Hospital, Australia | 16.30 - 16.50 | Sheway: An interdisciplinary response to improving outcomes for pregnant women who use substances Janine Hardial, Sheway Clinic, Vancouver, Canada | | |
| 16.45 - 17.15 | Questions & Discussion | | | | | | |
| 19:00 - 23:00 | Conference Dinner | | | | | | |

| | | | | | |
|--|--|--|--|---|--|
| Day 3 | | | | | |
| Moving beyond hepatitis C | | | | | |
| 09.30 - 11.00 Session S: Hepatitis C and Health for People who Use Drugs Room: Montreal Ballroom, Level 11 Chairs: Julie Bruneau and Marina Klein Chairs: Naveed Janjua and Laurence Marsillan | | | | | |
| 09.30 - 09.50 Beyond Hepatitis C: Improving the health and lives of people who use drugs Mark Tyndall, University of British Columbia, Canada | | | | | |
| 09.50 - 10.10 Health economics of substance use and hepatitis C: Informing practice and policy Bruce Schackman, Weill Cornell Medical College, United States | | | | | |
| 10.10 - 10.30 Questions & Discussion | | | | | |
| 10.30 - 10.45 Comparing adherence to once-daily and twice daily DAA therapy among people with recent injection drug use or current opioid substitution therapy: The SIMPLIFY and D3FEAT studies Evan Cunningham, The Kirby Institute, UNSW Sydney, Australia | | | | | |
| 10.45 - 11.00 Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: A pragmatic cluster randomised trial Andrew Radley, NHS Tayside, United Kingdom | | | | | |
| 11.00 - 11.30 Coffee Break and Poster Viewing Level 8 | | | | | |
| 11.30 - 12.00 Session T: 'Connecting with Care' – A Film Preview of Models of Care from Canada and beyond' Room: Montreal Ballroom, Level 11 Chairs: Conor Ashleigh | | | | | |
| 11.30 - 11.35 Introduction Conor Ashleigh, Visual Story Teller, Australia | | | | | |
| 11.35 - 11.40 The ENHANCE project, an intervention to increase hepatitis C diagnosis and treatment in Tehran, Iran Maryam Alavi, ENHANCE, Australia | | | | | |
| 11.40 - 11.45 Montreal's many models of care Julie Bruneau, CRISM, Canada; Hugo Bissonnet, Centre Sida Amitie, Canada; Martin Page, Dopamine, Canada | | | | | |
| 11.45 - 11.50 A Saskatchewan Story, Athahkakoop's Indigenous Model of Care Noreen Reed, Athahkakoop Clinic, Canada; Jennifer Ahenakew, Athahkakoop, Canada; Stuart Skinner, University Of Saskatchewan, Canada | | | | | |
| 11.50 - 12.00 Questions & Discussion | | | | | |
| 12.00 - 13.45 Lunch & Poster Viewing Level 8 | | | | | |
| 12.30 - 13.30 INHSU GAM Room: Fortifications, Level 9 | | | | | |
| 13.45 - 14.45 Session U: Hepatitis C reinfection Room: Montreal A & B, Level 11 Chairs: Charlotte Laniece and Phillip Read | | 13.45 - 14.45 Session V: Beyond hepatitis C Room: Montreal B & C, Level 11 Chairs: Sione Crawford and Sarah Larney | | 13.45 - 14.45 Session W: Models of care to enhance engagement in care Room: Fortifications, Level 9 Chairs: Lynn Taylor and Chris Fraser | |
| 13.45 - 14.00 Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in Canada Naveed Janjua, BC Centre For Disease Control, Canada | | 13.45 - 14.00 Operationalizing the risk environment: spatial distribution of people who inject drugs and hotspots of social injecting activity in Montreal, Canada Nanor Minoyan, University of Montréal CRCHUM, Canada | | 13.45 - 14.00 Community centric HCV testing and treatment for PWID in Manipur, India - The Head Start Project Babu Entroor Ramachandran, FIND, India | |
| 14.00 - 14.15 Risk of HCV reinfection and associated patterns of behaviour among men who inject drugs or who have sex with men in Canada Brendan Jacka, Research Institute, Centre hospitalier de l'Université de Montréal (CHUM), Canada | | 14.00 - 14.15 The impact of opioid agonist treatment on mortality among people who inject drugs: A 3 site modelling analysis Jack Stone, University Of Bristol, United Kingdom | | 14.00 - 14.15 'Get Tested LeEDs': (Re)-diagnosing and (re)-engaging PWID with blood borne viruses (BBV) in an urban emergency department Emma Page, Leeds Teaching Hospitals Trust, United Kingdom | |
| 14.15 - 14.30 Hepatitis C virus reinfection following antiviral treatment among people who use or inject drugs: a systematic review and meta-analysis Behzad Hajari, The Kirby Institute, UNSW Sydney, Australia | | 14.15 - 14.30 Growing old with drugs. Preliminary results from a qualitative study on the aging process of drug users in opioid substitution treatment Margheria Luciani, University Of Applied Sciences Of Southern Switzerland, Switzerland | | 14.15 - 14.30 Treating people where they are: Nurse-led hepatitis C (HCV) micro-elimination project for networks of people with recent injecting drug use in Victoria, Canada Karen Lundgren, Cool Aid Community Health Centre, Canada | |
| 14.30 - 14.35 Drug use and reinfection during and following HCV treatment with elbasvir/grazoprevir (EBV/GZR) among patients receiving opioid agonist therapy: Final results from the CO-STAR study Gregory Dore, The Kirby Institute, UNSW Sydney, Australia | | 14.30 - 14.35 Impacts of Hepatitis C Virus Infection Treatment for Patients in Treatment for Opioid Use Disorder Robert Heimer, Yale University School of Public Health, United States | | 14.30 - 14.35 A cost-benefit analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment Nick Scott, Burnet Institute, Australia | |
| 14.35 - 14.40 Low rate of reinfection among a cohort of people who inject drugs successfully treated for hepatitis C virus infection within a multidisciplinary program Brian Conway, Vancouver Infectious Disease Centre, Canada | | 14.35 - 14.40 An international systematic review of methadone and buprenorphine doses used in the treatment of opioid use disorder Sarah Larney, National Drug And Alcohol Research Centre, UNSW Sydney, Australia | | 14.35 - 14.40 Engaging mother-infant dyads in hepatitis C care through perinatal pediatric infectious diseases consultation Rachel Epstein, Boston Medical Center, United States | |
| 14.40 - 14.45 Rare HCV Re-Infection after DAA Treatment in an Integrated All-Under-One-Roof Care Setting Claudia Bernardini, ARUD, Switzerland | | 14.40 - 14.45 High Rates of Opioid Overdose and Witnessed Overdose in PWID Receiving HCV Treatment: Data from the ANCHOR Study Elana Rosenthal, University Of Maryland School Of Medicine, United States | | 14.40 - 14.45 Removing health insurance barriers and incorporating harm reduction with a physician - nurse - pharmacist team, to optimize hepatitis c virus (HCV) treatment in a U.S. co-located HCV/methadone maintenance program Jackie Habchi, Codac Behavioral Health, United States | |
| 14.45 - 15.15 Coffee Break and Poster Viewing | | | | | |
| 15.15 - 16.30 Session X: Beyond Injecting Drug Use Room: Montreal A & B, Level 11 Chairs: Suzanne Brissette and Philip Bruggmann | | 15.15 - 16.30 Session Y: How do we move forward policies on hepatitis C and drug use? Room: Montreal C & D, Level 11 Chairs: Jeffrey Lazarus and Annette Gaudino | | 15.15 - 16.30 Session Z: The critical role of the nurse for integrating health care for people who use drugs Room: Fortifications, Level 9 Chairs: Lesley Gallagher and Donna Zukowski | |
| 15.15 - 15.35 Emerging trends in stimulant use and the impact on hepatitis C Francisco Inacio Bastos, Oswaldo Cruz Foundation, Brazil | | 15.15 - 15.35 Policies to enhance access to hepatitis C prevention and treatment for people who use drugs Niklas Luhmann, World Health Organisation, Switzerland | | 15.15 - 15.30 Easy Access Within the Clinic and Corrections Janet Catt, Kings College Hospital NHS Foundation Trust, United Kingdom | |
| 15.35 - 15.55 Emerging Trends in alcohol and the impact on hepatitis C Jurgen Rehm, Centre for Addiction and Mental Health, Canada | | 15.35 - 15.55 Taking stock of a decade of drug policy: Where have we come and where to next? Marie Nougier, International Drug Policy Consortium, Country | | 15.30 - 15.45 Collaborating Within the Addiction Clinic Sidsel Sejr, KABS, Glostrup Kommune, Denmark | |
| 15.55 - 16.15 Emerging Trends in mental health and the impact on hepatitis C Didier Jutras-Aswad, Canadian Research Initiative in Substance Misuse (CRISM), Canada | | 15.55 - 16.15 Market dynamics and the hepatitis C response: Facilitating policy decisions to improve affordable, equitable access to treatment Sean Regan, Clinton Health Access Initiative, United States | | 15.45 - 16.00 Treat and Teach - Outreach to Indigenous Communities Lesley Gallagher, Saskatchewan Infectious Disease Care Network (SIDCN), Canada | |
| 16.15 - 16.30 Questions & Discussion | | 16.15 - 16.30 Questions & Discussion | | 16.00 - 16.15 The Independent Nurse Working as a Physician Delegate Jan Tait, Ninewells Hospital Dundee, United Kingdom | |
| | | | | 16.15 - 16.30 Managing HCV Elimination Heidi Friðriksdóttir, Landspítali University Hospital, Iceland | |
| 16.30 - 16.40 Room Movement | | | | | |
| 16.40 - 17.30 Conference Closing Room: Montreal Ballroom, Level 11 Chairs: Julie Bruneau and Marina Klein | | | | | |
| 16.40 - 16.50 Community Rapporteur | | | | | |
| 16.50 - 17.00 Policy & Epidemiology Rapporteur Jack Stone, University of Bristol, United Kingdom | | | | | |
| 17.00 - 17.10 Linkage to Care & Treatment Rapporteur Tracy Swan, Consultant United States | | | | | |
| 17.10 - 17.20 Models of Care Rapporteur John Dillon, University of Dundee, Scotland | | | | | |
| 17.20 - 17.30 Conference Closing and Introduction of Upcoming Conference | | | | | |